How Will Payers Manage The High Cost Of Combinations Of New Oncology Agents, As Many Of These Therapies Become The Preferred Treatment Options To Optimize Patient Outcomes?
Abstract
Authors
R Paglia A Del Carlo J Schwartz EA Carter C Foy S Dyson T Areteou